Invest in the future of medicine online and help ensure the safety of the patient on and offline.

Preventing patients ordering prescriptions with multiple online pharmacies.

Identifying counterfeit drugs and preventing their distribution into the Pharma chain.

Alerting patients instantly when a drug or medicine is recalled.

2019/05/15 00:00:00

MediConnect Public ICO is Live

Two Big Challenges within the Pharmaceutical Industry

The overuse of prescription medication

The overuse of prescription medication is increasing dramatically. This is because there are no control mechanisms in place to prevent patients purchasing prescribed medication from multiple sources, specifically in the private sector.

Currently, it is possible to be prescribed the same medicine from one or more online pharmacies as well as your regular NHS doctor.

Medication provenance and the pharmaceutical supply chain

Counterfeit drugs are increasingly available, and it can be difficult for the patient to establish provenance.

During the Casodex, Plavix and Zyprexa scandal of 2007, the Medicines and Health products Regulatory Agency (MHRA) seized 40,000 packs of fake medicine before they were distributed to pharmacies, but 25,000 packs reached pharmacies across the UK and were dispensed to patients. Following a recall, a further 7,000 packs were recovered.

Blockchain powered by

Who is MediConnect

After seeing first-hand the potential impact that the oversupply of medication, via NHS and private routes, can have. In January 2018 two online pharmacy owners and a superintendent pharmacy, discussed what could be done to stop these patients buying across multiple on and offline pharmacies.

“How can it be possible that a patient ordering a prescription from my website can then go on to your website and be prescribed the same medication 10 minutes later”? why is data not shared / why is the medication not flagged on a record? This is a question Joe Soiza asked his superintendent pharmacist along with his partners Eddie Dandy and Jason Timms another online pharmacy owner when they met to discuss the growing problem of drug dependency and addiction.

Jason then approached the MHRA, who internally discussed his proposal to have a single shared database to identify potential over prescribing. Impressed with the solution, they pointed him towards the CQC and Public Health England who were conducting a review of prescription drug addiction at the time and still are.

Dissatisfied with slow responses, Joe, Jason & Eddie decided to invest in a solution to the problem and working with their independent teams they eventually collaborated and formed MediConnect. Stratis were approached for advice and as a potential platform to use however, Chris Trew the CEO of Stratis was so impressed with the solution and opportunity to prevent dependency and potential addiction of prescription drugs, he joined the MediConnect team as advisor and Stratis will now provide a bespoke blockchain solution.

Learn more about who we are and what we do in our latest whitepaper.

Who is MediConnect

After seeing first-hand the potential impact that the oversupply of medication, via NHS and private routes, can have. In January 2018 two online pharmacy owners and a superintendent pharmacy, discussed what could be done to stop these patients buying across multiple on and offline pharmacies.
[expander_maker id=”1″ more=”Read more” less=”Read less”]
“How can it be possible that a patient ordering a prescription from my website can then go on to your website and be prescribed the same medication 10 minutes later”? why is data not shared / why is the medication not flagged on a record? This is a question Joe Soiza asked his superintendent pharmacist along with his partners Eddie Dandy and Jason Timms another online pharmacy owner when they met to discuss the growing problem of drug dependency and addiction.

Jason then approached the MHRA, who internally discussed his proposal to have a single shared database to identify potential over prescribing. Impressed with the solution, they pointed him towards the CQC and Public Health England who were conducting a review of prescription drug addiction at the time and still are.

Dissatisfied with slow responses, Joe, Jason & Eddie decided to invest in a solution to the problem and working with their independent teams they eventually collaborated and formed MediConnect. Stratis were approached for advice and as a potential platform to use however, Chris Trew the CEO of Stratis was so impressed with the solution and opportunity to prevent dependency and potential addiction of prescription drugs, he joined the MediConnect team as advisor and Stratis will now provide a bespoke blockchain solution.

[/expander_maker]

Learn more about who we are and what we do in our latest whitepaper.

Register for Public ICO now

Connecting the Pharma World

MediConnect is the only blockchain solution intended to revolutionise the use of medication in the UK.

It will prevent the over-prescribing to patients of medication from multiple pharmacies, reduce addiction, provide traceability of drugs from manufacturers, wholesalers, prescribers and pharmacies all the way through to patients. This will enable the removal of false medicines and the easy recall of drugs within the Pharma system.


Drug Recalls

 

The current drug recall system by the MHRA is very effective within the industry channels, allowing the effective recall of drugs from manufacturers to wholesal …


False Medicines

 

From falsified Lipitor tablets to imitation Viagra and Cialis capsules, counterfeit pharmaceuticals are a €188 billion (US$200 billion) annual business, making …


Reducing Addiction

 

Addiction is fast becoming a health issue in the UK, particularly to Opiate pain killers and sleep-inducing medication. The over use of prescription medication …

Connecting the Pharma World

MediConnect is the only blockchain solution intended to revolutionise the use of medication in the UK.

It will prevent the over-prescribing to patients of medication from multiple pharmacies, reduce addiction, provide traceability of drugs from [expander_maker id=”1″ more=”Read more” less=”Read less”]manufacturers, wholesalers, prescribers and pharmacies all the way through to patients. This will enable the removal of false medicines and the easy recall of drugs within the Pharma system.

 


Drug Recalls

 

The current drug recall system by the MHRA is very effective within the industry channels, allowing the effective recall of drugs from manufacturers to wholesal …


False Medicines

 

From falsified Lipitor tablets to imitation Viagra and Cialis capsules, counterfeit pharmaceuticals are a €188 billion (US$200 billion) annual business, making …


Reducing Addiction

 

Addiction is fast becoming a health issue in the UK, particularly to Opiate pain killers and sleep-inducing medication. The over use of prescription medication …

[/expander_maker]

Market validation

€188bn

counterfeit medication business annually

50%

of drugs sold online are fraudulent (WHO)

43%

online prescribers were unsafe

3.1m

Brits were prescribed opioids in 2017 – an 80% rise on the 2007 figure.

£263m

cost of opioids to the taxpayer

200k

Brits are said to be chronic prescription painkiller users

60+

hospital admissions every day due to overdoses – almost doubled in a decade

17,000

lives claimed by America’s opioid crisis in 2016

The Safety Net for Patients, Prescribers, Pharmacies and Drug Manufacturers.

With all the regulatory bodies within the Pharmacy sector recognising and concerned about the growing issue of over-prescribing of prescription medication online, MediConnect can offer a solution to this growing problem almost immediately.

Prescribers & pharmacies using MediConnect will have the confidence that by using our blockchain solution, the misuse and over-prescribing of prescription medication to potential addicts – who would normally shop around online for medication – will be eliminated.

Patients will be given the assurance that the medication they are being prescribed is genuine and from a licensed manufacturer, prescriber and pharmacy that is using a gold-standard solution to help improve their own duty of care.

The Safety Net for Patients, Prescribers, Pharmacies and Drug Manufacturers.

With all the regulatory bodies within the Pharmacy sector recognising and concerned about the growing issue of over-prescribing of prescription medication online, MediConnect can offer a solution to this growing problem almost immediately.
[expander_maker id=”1″ more=”Read more” less=”Read less”]
Prescribers & pharmacies using MediConnect will have the confidence that by using our blockchain solution, the misuse and over-prescribing of prescription medication to potential addicts – who would normally shop around online for medication – will be eliminated.

Patients will be given the assurance that the medication they are being prescribed is genuine and from a licensed manufacturer, prescriber and pharmacy that is using a gold-standard solution to help improve their own duty of care.

“It’s incredibly concerning to hear reports of patients buying prescription drugs online, often from unverified websites, with minimal security checks in place and with decisions being made by prescribers who are unfamiliar with the person they are prescribing for.”

(Pulse, March 2018)

Helen Stokes-Lampard
Chair of the Royal College of General Practitioners

[/expander_maker]

How our Blockchain Works

Benefits of the MediConnect offering

Our Launch Partners and Regulators

Starting in the first quarter of 2019, following the ICO, MediConnect will commence working with two online pharmacies in the UK.

The blockchain solution will start integrating with UK Meds and Tower Health & Pharmacy based in Nottingham. This trial, the first of its kind, will provide 360,000 patients the opportunity to have their records stored securely on the blockchain with 50,000 transactions being added every month.

UK Meds has quickly established itself as one of the UK’s largest online pharmacies, having dispensed nearly half a million prescriptions to a patient base of 200,000. Tower Health & Pharmacy have been established as a health provider for over 18 years, offering both alternative solutions as well as NHS and private prescriptions.

The priority for both these pharmacies is duty of care. This, combined with their rapid growth and ability to invest in IT solutions to improve patient outcomes, places these two pharmacies as the clear choice to be the first to launch on the MediConnect platform.

They understand that success in a patient-centric business, delivering services that are fundamental to their customers’ wellbeing, depends not only on operational excellence, but also on collaboration with the NHS and other stakeholders across the supply chain.

“This blockchain solution can offer new opportunities to the consumer in terms of how they transact and how they manage their own medical data, it also provides a gold standard in patient safety and duty of care. Here at UK Meds we are really excited about being the first of hundreds of pharmacies to challenge prescription drug addiction.”

Joe Soiza
Founder UK Meds

UK Meds - UK's Leading Online Pharmacy

Our Launch Partners and Regulators

Starting in the first quarter of 2019, following the ICO, MediConnect will commence working with two online pharmacies in the UK.

The blockchain solution will start integrating with UK Meds and Tower Health & Pharmacy based in[expander_maker id=”1″ more=”Read more” less=”Read less”] Nottingham. This trial, the first of its kind, will provide 360,000 patients the opportunity to have their records stored securely on the blockchain with 50,000 transactions being added every month.

UK Meds has quickly established itself as one of the UK’s largest online pharmacies, having dispensed nearly half a million prescriptions to a patient base of 200,000. Tower Health & Pharmacy have been established as a health provider for over 18 years, offering both alternative solutions as well as NHS and private prescriptions.

The priority for both these pharmacies is duty of care. This, combined with their rapid growth and ability to invest in IT solutions to improve patient outcomes, places these two pharmacies as the clear choice to be the first to launch on the MediConnect platform.

They understand that success in a patient-centric business, delivering services that are fundamental to their customers’ wellbeing, depends not only on operational excellence, but also on collaboration with the NHS and other stakeholders across the supply chain.

“This blockchain solution can offer new opportunities to the consumer in terms of how they transact and how they manage their own medical data, it also provides a gold standard in patient safety and duty of care. Here at UK Meds we are really excited about being the first of hundreds of pharmacies to challenge prescription drug addiction.”

Joe Soiza
Founder UK Meds

[/expander_maker]

Supporting Industry Change

The MediConnect Live pilot is in partnership with the newly formed Addiction Safeguarding Committee. The ASC is a collaborative not-for-profit organisation.

The primary outputs for the ASC will include, but are not limited to:

  • The initiation of a Feasibility Trial to include 8-10 local private and NHS pharmacies to scope the data concept in the real world.
  • The creation and mandatory use of “one” evidential-standard and “tamper-evident” transaction records that are highly distributed and potentially visible to all in the chain of distributing and prescribing.
  • Identification of a protocol that can be extrapolated onto a national stage.

MediConnect have agreed a contract with the newly formed Addiction Safeguarding Committee, providing the blockchain solution to help them meet their challenge through a pilot scheme to share data across both independent and NHS prescribers & Pharmacies in the East Midlands.

Members of the local Healthcare professional bodies, CQC, LPC, GPhC, and Public Health England have been invited to meet to scope out the framework for the Addiction Safeguarding Committee within the Nottinghamshire area, under the Chairmanship of Professor John Hunt, BSc, PhD, DSc. FRSC.

The purpose of this collaborative ASC working group is to identify, analyse, report on and recommend requirements to local health authorities to help address prescription drug addiction challenges through the better use of quality data across a community of local government, industry, local organisations and patients.

MediConnect is quite clearly best placed to support the requirements of the ASC, to not only reduce time and monetary cost for healthcare providers, it could also improve ‘Patient Confidence’ in the system, as well as fulfilling the professional ‘Duty of Care’.

MediConnect have agreed in principle a 5-year service agreement to support the requirements of this local initiative starting in Q2 of 2019.

“This blockchain solution can offer new opportunities to the consumer in terms of how they transact and how they manage their own medical data, it also provides a gold standard in patient safety and duty of care. Here at UK Meds we are really excited about being the first of hundreds of pharmacies to challenge prescription drug addiction.”

Joe Soiza
Founder UK Meds

Supporting Industry Change

The MediConnect Live pilot is in partnership with the newly formed Addiction Safeguarding Committee. The ASC is a collaborative not-for-profit organisation.

The primary outputs for the ASC will include, but are not limited to:[expander_maker id=”1″ more=”Read more” less=”Read less”]

  • The initiation of a Feasibility Trial to include 8-10 local private and NHS pharmacies to scope the data concept in the real world.
  • The creation and mandatory use of “one” evidential-standard and “tamper-evident” transaction records that are highly distributed and potentially visible to all in the chain of distributing and prescribing.
  • Identification of a protocol that can be extrapolated onto a national stage.

MediConnect have agreed a contract with the newly formed Addiction Safeguarding Committee, providing the blockchain solution to help them meet their challenge through a pilot scheme to share data across both independent and NHS prescribers & Pharmacies in the East Midlands.

Members of the local Healthcare professional bodies, CQC, LPC, GPhC, and Public Health England have been invited to meet to scope out the framework for the Addiction Safeguarding Committee within the Nottinghamshire area, under the Chairmanship of Professor John Hunt, BSc, PhD, DSc. FRSC.

The purpose of this collaborative ASC working group is to identify, analyse, report on and recommend requirements to local health authorities to help address prescription drug addiction challenges through the better use of quality data across a community of local government, industry, local organisations and patients.

MediConnect is quite clearly best placed to support the requirements of the ASC, to not only reduce time and monetary cost for healthcare providers, it could also improve ‘Patient Confidence’ in the system, as well as fulfilling the professional ‘Duty of Care’.

MediConnect have agreed in principle a 5-year service agreement to support the requirements of this local initiative starting in Q2 of 2019.

“This blockchain solution can offer new opportunities to the consumer in terms of how they transact and how they manage their own medical data, it also provides a gold standard in patient safety and duty of care. Here at UK Meds we are really excited about being the first of hundreds of pharmacies to challenge prescription drug addiction.”

Joe Soiza
Founder UK Meds

[/expander_maker]

At the heart of regulatory change

In 2017 the Lord Holmes report ‘Distributed Ledger Technology for Public Good: leadership, innovation and collaboration’ and the HMG Government Office of Science report ‘Distributed Ledger Technology: Beyond blockchain’ look forward and call for several enablers to exist to support development of DLT across governments organisations, law enforcement and industries, including consumers.

The BBFA are co-organising and supporting a number of community-specific collaborative working groups to support the Lord Holmes’ call to action.

  • An official BBFA Prescription Drug Addiction working group has now been formed by MediConnect with Jason Timms as Chair, which will meet monthly to form a set of governance principles around the sharing, management and protection of this data to enable supply chain collaboration and innovation; and generation of regulatory compliance data as a by-product of normal business data.
  • Create a roadmap of steps towards the implementation of a patient centric safety policy against the mis-use and over prescribing of medication online

As MediConnect is a steering group with in the BBFA, we sit on the other working groups to ensure we stay compliant and ahead of proposed regulatory change. Identity, Privacy, Assurance, Cybersecurity and Data Quality group participation will keep us close to this change and ensure our blockchain solution will be adopted in the Pharma sector.

All the major regulators have been invited to contribute to the framework of working group to enable MediConnect’s vision of the blockchain solution eventually being the gold standard solution.

These regulatory bodies can also assist the purpose of this Prescription Drug Addiction working group report on and make recommendations to the BBFA and in turn government on:

  • Reducing and addressing addiction
  • Prevent misuse and over prescribing of prescription drugs
  • Provide visibility to all through the streamlining of the drug recall process
  • Establish drug provenance identification
  • Establish requirements for educational awareness and guidance for GPs and prescribing organisations
  • Establish risk mitigation requirements to prevent patient manipulation of GPs and prescribing organisations.

The Working Group will also benefit from the latest information on developing standards and international activities.

MediConnect are members of the BBFA. The BBFA is tasked with Contributing to Lord Holmes Report ‘Distributed Ledger Technologies for Public Good: leadership, collaboration and innovation’, which builds on UK Government Office for Science (Sir Mark Walport) ‘Distributed Ledger Technologies: beyond blockchain’ (BBFA co-authored).

At the heart of regulatory change

In 2017 the Lord Holmes report ‘Distributed Ledger Technology for Public Good: leadership, innovation and collaboration’ and the HMG Government Office of Science report ‘Distributed Ledger Technology: Beyond blockchain’ look forward and call for several enablers to exist to support development of DLT across [expander_maker id=”1″ more=”Read more” less=”Read less”] governments organisations, law enforcement and industries, including consumers.

The BBFA are co-organising and supporting a number of community-specific collaborative working groups to support the Lord Holmes’ call to action.

  • An official BBFA Prescription Drug Addiction working group has now been formed by MediConnect with Jason Timms as Chair, which will meet monthly to form a set of governance principles around the sharing, management and protection of this data to enable supply chain collaboration and innovation; and generation of regulatory compliance data as a by-product of normal business data.
  • Create a roadmap of steps towards the implementation of a patient centric safety policy against the mis-use and over prescribing of medication online

As MediConnect is a steering group with in the BBFA, we sit on the other working groups to ensure we stay compliant and ahead of proposed regulatory change. Identity, Privacy, Assurance, Cybersecurity and Data Quality group participation will keep us close to this change and ensure our blockchain solution will be adopted in the Pharma sector.

All the major regulators have been invited to contribute to the framework of working group to enable MediConnect’s vision of the blockchain solution eventually being the gold standard solution.

These regulatory bodies can also assist the purpose of this Prescription Drug Addiction working group report on and make recommendations to the BBFA and in turn government on:

  • Reducing and addressing addiction
  • Prevent misuse and over prescribing of prescription drugs
  • Provide visibility to all through the streamlining of the drug recall process
  • Establish drug provenance identification
  • Establish requirements for educational awareness and guidance for GPs and prescribing organisations
  • Establish risk mitigation requirements to prevent patient manipulation of GPs and prescribing organisations.

The Working Group will also benefit from the latest information on developing standards and international activities.

MediConnect are members of the BBFA. The BBFA is tasked with Contributing to Lord Holmes Report ‘Distributed Ledger Technologies for Public Good: leadership, collaboration and innovation’, which builds on UK Government Office for Science (Sir Mark Walport) ‘Distributed Ledger Technologies: beyond blockchain’ (BBFA co-authored).

[/expander_maker]

Token Details

Symbol / Ticker MEDI
Max Supply 500,000,000 MEDI
Platform Stratis
Public sale date 20th February 2019
Public sale end date 15th May 2019

Allocation of Tokens

Allocation of Funds

The team

Dexter Blackstock 
Mediconnect Director

Joe Soiza
UK Meds Owner and Healthcare Visionary

Jason Timms
PHZ Group Owner & Visionary

Chris Trew
CEO and Founder of Stratis Group Ltd

Shyam Morjaria MRPharmS
Superintendent Pharmacist & Head of Purchasing

Samuel Ogunsalu
Advisor

Eddie Dandy B Pharm, MBA, PDip.Clin.
Superintendent Pharmacist

Patrick Curry OBE
CEO, British Business Federation Authority (BBFA)

Team

Roadmap

2018

Q1

Conceived Idea and scoped out requirements of a Prescription Drug Addiction Database.

Q2

Agreed blockchain platform partnership with Stratis.

Q3

Presented idea of a regional trial of East Midlands Pharmacies with newly formed Nottingham Addiction Safeguarding Committee.

Q4

Jason Timms appointed chair of the official Prescription Drug Addiction (PDA) Working Group with the BBFA to tackle over prescribing, drug recalls, counterfeit drug reduction.

Agreed contract start date with ASC Nottingham for Q2 2019 and the onboarding of 2 Pharmacies to MediConnect.

Attended all Chairperson Meeting of the BBFA working groups to look at collaborative opportunities of the PDA on legal, identity, master data, assurance and Cybersecurity working groups.

2019

Q1

ICO Public Sale.

PDA Working Group meeting – Invites to attend to CQC, MHRA, GPhC, LPC, Pharma wholesale and retail industry.

Q2

Commence contract with the ASC to support the Nottingham Trial and UK roll out programme.

Tower Pharmacy & UK Meds will be first 2 Pharmacies on the ASC blockchain solution from MediConnect.

6 other Pharmacies will be integrated, including 1 NHS Hospital outpatient dispensing pharmacy.

Q3

Collaboration with Local Pharmacy Groups and membership committee to inform on pilot and expand reach to 20 further pharmacies in Nottingham, Derby & Leicester.

Partnership with Pharmacy Wholesaler – implementation of drug recall and counterfeit medication system.

Q4

Publish trial research and outcomes – present at PDA meeting to CQC, MHRA. GPhC, LPC and Industry.

2020

Q1

The MediConnect platform will demonstrate an improved duty of care and detection that will see a reduction in pharmacy insurance for Pharmacies.

Q2

Will see the recruitment of 500 UK Pharmacies join MediConnect through the expansion of the ASC membership in the UK.

Q3

Aim for MediConnect to be the Industry standard solution for traceability of drugs for recall and counterfeit medication detection.

Q4

The ASC achieves it’s goal of UK Pharmacies required to be members of the ASC and the MediConnect platform is used by all UK pharmacies

MediConnect in the Press